SRR25617825
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.320
- PANCREAS_BETA_CELLS+0.320
- ALLOGRAFT_REJECTION+0.300
- INTERFERON_ALPHA_RESPONSE+0.270
- KRAS_SIGNALING_DN+0.250
- SPERMATOGENESIS+0.240
- BILE_ACID_METABOLISM+0.210
- E2F_TARGETS+0.200
- MYC_TARGETS_V1+0.190
- G2M_CHECKPOINT+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- HEDGEHOG_SIGNALING-0.500
- UV_RESPONSE_DN-0.480
- APICAL_SURFACE-0.440
- TGF_BETA_SIGNALING-0.430
- APICAL_JUNCTION-0.410
- NOTCH_SIGNALING-0.410
- ANGIOGENESIS-0.390
- MYOGENESIS-0.380
- WNT_BETA_CATENIN_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c94686d5.355c.432f.bc98.ccdd30a209de | — | cohortA4 | 0.828 |
| 2 | TCGA-EW-A1J6-01A-11R-A13Q-07 | — | B | 0.815 |
| 3 | TCGA-AR-A0TV-01A-21R-A084-07 | — | B | 0.811 |
| 4 | SRR8518222 | — | D | 0.810 |
| 5 | d7472c45-93c1-4237-82ac-c17e863b9a58 | — | — | 0.806 |
| 6 | TCGA-69-8255-01A-11R-2287-07 | — | cohortA4 | 0.806 |
| 7 | SRR1313162 | — | C | 0.801 |
| 8 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.795 |
| 9 | MNG15 | — | — | 0.785 |
| 10 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |